Bijal Shah, MD, on AUTO1 in R/R B-Cell ALL and the FELIX Trial
Shah explained that the trial is unique due to its inclusion of patients with MRD–positive B-ALL.
This content originally appeared on our sister site,
AUTO1 (CAT19-41BB-Z CAR T-cells) is an autologous low-affinity CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy being evaluated in the phase 1/2 FELIX trial (NCT04404660) for the treatment of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). The trial is unique due to its inclusion of patients with minimal residual disease (MRD)–positive B-ALL in 1 of its cohorts.
In an interview with OncLive, Bijal Shah, MD, MS, associate member, Department of Malignant Hematology, Moffitt Cancer Center, discussed the trial's importance. He explained that the inclusion of these patients is based on multiple retrospective observations indicating that patients with low disease burden have the best outcomes in terms of toxicity, response, and duration of response. Shah also clarified that "low disease burden" ideally referes to undectable disease in this context.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025
- Around the Helix: Cell and Gene Therapy Company Updates – September 10, 2025
September 10th 2025